|
1.
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A,
Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Mirimanoff RO, Gorlia T, Mason W, Van den
Bent MJ, Kortmann RD, Fisherb, Reni M, Brandes AA, Curschmann J,
Villa S, Cairncross G, Allgerer A, Lacombe D and Stupp R:
Radiotherapy and temozolomide for newly diagnosed glioblastoma:
recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3
phase III randomized trial. J Clin Oncol. 24:2563–2569. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkeiman RM, Cusimano MD and Dirks PB:
Identification of human tumor initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Galli R, Binda E, Orfanelli U, Cipelletti
B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi
A: Isolation and characterization of tumorigenic, stem-like neural
precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Singh SK, Clark ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
6.
|
Clark MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future derections:
AACR workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Lee J, Kotliarova S, Kotliarov Y, Li A, Su
Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, Park JK
and Fine HA: Tumor stem cells derived from glioblastomas cultures
in bFGF and EGF more closely mirror the phenotype and genotype of
primary tumors than do serum-cultured cell lines. Cancer Cells.
9:391–403. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Brennan C, Momota H, Hambardzumyan D,
Ozawa T, Tandon A, Pedraza A and Holland E: Glioblastoma subclasses
can be defined by activity among signal transduction pathways and
associated genomic alterations. PLoS One. 4:e77522009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Cheng CK, Fan QW and Weiss WA: PI3K
signaling in glioma-animal models and therapeutic challenges. Brain
Pathol. 19:112–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Demuth T, Reavie LB, Rennert JL, Nakada M,
Nakada S, Hoelzinger DB, Beaudry CE, Henrichs AN, Anderson EM and
Berens ME: MAP-ing glioma invasion: mitogen-activated protein
kinase 3 and p38 drive glioma invasion and progression and predict
patient survival. Mol Cancer Ther. 6:1212–1222. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Pu P, Zhang Z, Kang C, Jiang R, Jia Z,
Wang G and Jiang H: Downregulation of Wnt2 and beta-catenin by
siRNA suppresses malignant glioma cell growth. Cancer Gene Ther.
16:351–361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Purow BW, Haque RM, Noel MW, Su Q, Burdick
MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric
D, Eberhart CG and Fine HA: Expression of Notch-1 and its ligands,
Delta-like-1 and Jagged-1, is critical for glioma cell survival and
proliferation. Cancer Res. 65:2353–2363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Zhong Z, Wen L and Darnell JE Jr: Stat3
and Stat4: members of the family of signal transducers and
activators of transcription. Proc Natl Acad Sci USA. 91:4806–4810.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Sherry MM, Reeves A, Wu JK and Cochran BH:
STAT3 is required for proliferation and maintenance of multipotency
in glioblastoma stem cells. Stem Cells. 27:2383–2392. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Li GH, Wei H, Lv SQ, Ji H and Wang DL:
Knockdown of STAT3 expression by RNAi suppresses growth and induces
apoptosis and differentiation in glioblastoma stem cells. Int J
Oncol. 37:103–110. 2010.PubMed/NCBI
|
|
16.
|
Ashizawa T, Miyata H, Ishii H, Oshita C,
Matsuno K, Masuda Y, Furuya T, Okawara T, Otsuka M, Ogo N, Asai A
and Akiyama Y: Antitumor activity of a novel small molecule STAT3
inhibitor against a human lymphoma cell line with high STAT3
activation. Int J Oncol. 38:1245–1252. 2011.PubMed/NCBI
|
|
17.
|
Matsuno K, Masuda Y, Uehara Y, Sato H,
Muroya A, Takahashi O, Yokotagawa T, Furuya T, Okawara T, Otsuka M,
Ogo N, Ashizawa T, Oshita C, Tai S, Ishii H, Akiyama Y and Asai A:
Identification of a new series of STAT3 inhibitors by virtual
screening. ACS Med Chem Lett. 1:371–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Carro MS, Lim WK, Alvarez MJ, Bollo RJ,
Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H,
Lasorella A, Aldape K, Califano A and Lavarone A: Transcriptional
network for mesenchymal transformation of brain tumors. Nature.
463:318–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao
Y, Kalvakolanu DV, Kopecko DJ, Zhao X and Xu DQ: Down-regulation of
signal transducer and activator of transcription 3 expression using
vector-based small interfering RNAs suppresses growth of human
prostate tumor in vivo. Clin Cancer Res. 11:6333–6341. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ling X and Arlinghaus RB: Knockdown of
STAT3 expression by RNA interference inhibits the induction of
breast tumors in immunocompetent mice. Cancer Res. 65:2532–2536.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Ohka F, Natsume A and Wakabayashi T:
Current trends in targeted therapies for glioblastoma multiforme.
Neurol Res Int. 2012. View Article : Google Scholar
|
|
22.
|
Takizawa T, Nakashima K, Namihira M,
Ochiai W, Uemura A, Yanagisawa M, Fujita N, Nakao M and Taga T: DNA
methylation is a critical cell-intrinsic determinant of astrocyte
differentiation in the fetal brain. Dev Cell. 1:749–758. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
De la Iglesia N, Konopka G, Puram SV, Chan
JA, Bachoo RM, You MJ, Levy DE, Depinho RA and Bonni A:
Identification of a PTEN-regulated STAT3 brain tumor suppressor
pathway. Genes Dev. 22:449–462. 2008.PubMed/NCBI
|
|
24.
|
Ikushima H, Todo T, Ino Y, Takahashi M,
Saito N, Miyazaki K and Miyazono K: Glioma-initiating cells retain
their tumorigenicity through integration of the Sox axis and Oct4
protein. J Biol Chem. 286:41434–41441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Guo Y, Mantel C, Hromas RA and Broxmeyer
HE: Oct-4 is critical for survival/antiapoptosis of murine
embryonic stem cells subjected to stress: effects associated with
Stat3/survivin. Stem Cells. 26:30–34. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Zhao W, Hisamuddin IM, Nandan MO, Babbin
BA, Lamb NE and Yang VW: Identification of Krüppel-like factor 4 as
a potential tumor suppressor gene in colorectal cancer. Oncogene.
23:395–402. 2004.
|
|
27.
|
McFarland BC, Ma JY, Langford CP,
Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D and Benveniste EN:
Therapeutic potential of AZD1480 for the treatment of human
glioblastoma. Mol Cancer Ther. 10:2384–2393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Sai K, Wang S, Balasubramaniyan V, Conrad
C, Lang FF, Aldape K, Szymanski S, Fokt I, Dasgupta A, Madden T,
Guan S and Chen Z: Induction of cell-cycle arrest and apoptosis in
glioblastoma stem-like cells by WP1193, a novel small molecule
inhibitor of the JAK2/STAT3 pathway. J Neurooncol. 107:487–501.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Ball S, Li C, Li PK and Lin J: The small
molecule, LLL12, inhibits STAT3 phosphorylation and induces
apoptosis in medulloblastoma and glioblastoma cells. PLoS One.
6:e188202011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Zhuang W, Long L, Zheng B, Ji W, Yang N,
Zhang Q and Liang Z: Curcumin promotes differentiation of
glioma-initiating cells by inducing autophagy. Cancer Sci.
103:684–690. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Denysenko T, Gennero L, Roos MA, Melcarne
A, Juenemann C, Faccani G, Morra I, Cavallo G, Reguzzi S,
Pescarmona G and Ponzetto A: Glioblastoma cancer stem cells:
heterogeneity, microenvironment and related therapeutic strategies.
Cell Biochem Funct. 28:343–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Hofstetter CP, Burkhardt JK, Shin BJ,
Gursel DB, Mubita L, Gorrepati R, Brennan C, Holland EC and
Boockvar JA: Protein phosphatase 2A mediates dormancy of
glioblastoma multiforme-derived tumor stem-like cells during
hypoxia. PLoS One. 7:e300592012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Wu Y, Richrad JP, Wang SD, Rath P, Laterra
J and Xia S: Regulation of glioblastoma multiforme stem-like cells
by inhibitor of DNA binding proteins and oligodendroglial
lineage-associated transcription factors. Cancer Sci.
103:1028–1037. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Nguyen V, Conyers JM, Zhu D, Gibo DM,
Dorsey JF, Debinski W and Mintz A: IL-13Rα2-targeted therapy
escapees: biologic and therapeutic implications. Transl Oncol.
4:390–400. 2011.
|
|
35.
|
Natsume A, Kato T, Kinjo S, Enomoto A,
Toda H, Shimato S, Ohka F, Motomura K, Kondo Y, Miyata T, Takahashi
M and Wakabayashi T: Girdin maintains the stemness of glioblastoma
stem cells. Oncogene. 31:2715–2724. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Pistollato F, Abbadi S, Rampazzo E,
Persano L, Della Puppa A, Frasson C, Sarto E, Scienza R, D’Avella D
and Basso G: Intratumoral hypoxic gradient drives stem cells
distribution and MGMT expression in glioblastoma. Stem Cells.
28:851–862. 2010.PubMed/NCBI
|
|
37.
|
Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang
YJ, Zhao L, Chen FH, Wang XT, You QD and Guo QL: HIF-1α is critical
for hypoxia-mediated maintenance of glioblastoma stem cells by
activating Notch signaling pathway. Cell Death Differ. 19:284–294.
2012.
|
|
38.
|
Ikushima H, Todo T, Ino Y, Takahashi M,
Miyazawa K and Miyazono K: Autocrine TGF-β signaling maintains
tumorigenicity of glioma-initiating cells through Sry-related
HMG-box factors. Cell Stem Cell. 5:504–514. 2009.
|
|
39.
|
Kaur H, Phillips-Mason PJ, Burden-Gulley
SM, Kerstetter-Fogle AE, Basilion JP, Sloan AE and Brady-Kalnay SM:
Cadherin-11, a marker of the mesenchymal phenotype, regulates
glioblastoma cell migration and survival in vivo. Mol Cancer Res.
10:293–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Cheng WY, Kandel JJ, Yamshiro DJ, Canoll P
and Anastassiou D: A multi-cancer mesenchymal transition gene
expression signature is associated with prolonged time to
recurrence in glioblastoma. PLoS One. 7:e347052012. View Article : Google Scholar : PubMed/NCBI
|
